Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.

BACKGROUND & AIMS Intraductal papillary mucinous neoplasms (IPMNs) are regarded as precursors of pancreatic ductal adenocarcinomas (PDAs), but little is known about the mechanism of progression. This makes it challenging to assess cancer risk in patients with IPMNs. We investigated associations of IPMNs with concurrent PDAs by genetic and histologic analyses. METHODS We obtained 30 pancreatic tissues with concurrent PDAs and IPMNs, and 168 lesions, including incipient foci, were mapped, microdissected, and analyzed for mutations in 18 pancreatic cancer-associated genes and expression of tumor suppressors. RESULTS We determined the clonal relatedness of lesions, based on driver mutations shared by PDAs and concurrent IPMNs, and classified the lesions into 3 subtypes. Twelve PDAs contained driver mutations shared by all concurrent IPMNs, which we called the sequential subtype. This subset was characterized by less diversity in incipient foci with frequent GNAS mutations. Eleven PDAs contained some driver mutations that were shared with concurrent IPMNs, which we called the branch-off subtype. In this subtype, PDAs and IPMNs had identical KRAS mutations but different GNAS mutations, although the lesions were adjacent. Whole-exome sequencing and methylation analysis of these lesions indicated clonal origin with later divergence. Ten PDAs had driver mutations not found in concurrent IPMNs, called the de novo subtype. Expression profiles of TP53 and SMAD4 increased our ability to differentiate these subtypes compared with sequencing data alone. The branch-off and de novo subtypes had substantial heterogeneity among early clones, such as differences in KRAS mutations. Patients with PDAs of the branch-off subtype had a longer times of disease-free survival than patients with PDAs of the de novo or the sequential subtypes. CONCLUSIONS Detailed histologic and genetic analysis of PDAs and concurrent IPMNs identified 3 different pathways by which IPMNs progress to PDAs-we call these the sequential, branch-off, and de novo subtypes. Subtypes might be associated with clinical and pathologic features and be used to select surveillance programs for patients with IPMNs.

[1]  M. Mino‐Kenudson,et al.  Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism , 2018, Nature Cell Biology.

[2]  David L. Masica,et al.  IPMNs with co-occurring invasive cancers: neighbours but not always relatives , 2018, Gut.

[3]  Jin‐Young Jang,et al.  of the pancreas , 2017 .

[4]  K. Ando,et al.  An improved digital polymerase chain reaction protocol to capture low‐copy KRAS mutations in plasma cell‐free DNA by resolving ‘subsampling’ issues , 2017, Molecular oncology.

[5]  T. Ohtsuka,et al.  Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2017, Annals of surgery.

[6]  N. Bardeesy,et al.  Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm , 2017, Clinical and translational gastroenterology.

[7]  M. Büchler,et al.  Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. , 2016, Gastroenterology.

[8]  T. Ohtsuka,et al.  Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers , 2016, Pancreas.

[9]  A. Gelrud,et al.  Risk of pancreatic cancer in patients with pancreatic cyst. , 2016, Gastrointestinal endoscopy.

[10]  Shane D. Marine,et al.  USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds , 2016, Proceedings of the National Academy of Sciences.

[11]  K. Semba,et al.  GNASR201H and KrasG12D cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm , 2016, Oncogene.

[12]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[13]  Satoru Miyano,et al.  Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution , 2016, PLoS genetics.

[14]  Jin‐Young Jang,et al.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. , 2016, Annals of surgery.

[15]  A. Krasinskas,et al.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas , 2015, The American journal of surgical pathology.

[16]  Jin-Young Jang,et al.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts. , 2015, Gastroenterology.

[17]  Rosane Minghim,et al.  InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams , 2015, BMC Bioinformatics.

[18]  M. Berger,et al.  GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. , 2015, Journal of the American College of Surgeons.

[19]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[20]  P. Moayyedi,et al.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. , 2015, Gastroenterology.

[21]  Masao Tanaka,et al.  Management of pancreatic cysts: the evidence is not here yet. , 2015, Gastroenterology.

[22]  Masakazu Yamamoto,et al.  Molecular Biomarkers for Progression of Intraductal Papillary Mucinous Neoplasm of the Pancreas , 2015, Pancreas.

[23]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[24]  Masakazu Yamamoto,et al.  Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas , 2015, Modern Pathology.

[25]  K. Nagashima,et al.  Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs) , 2015, The journal of pathology. Clinical research.

[26]  Rita T Lawlor,et al.  Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas , 2014, The Journal of pathology.

[27]  G. Dotto.  Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. , 2014, The Journal of clinical investigation.

[28]  G. Kristiansen,et al.  GNAS Sequencing Identifies IPMN-specific Mutations in a Subgroup of Diminutive Pancreatic Cysts Referred to as “Incipient IPMNs” , 2014, The American journal of surgical pathology.

[29]  Timothy B Lannin,et al.  Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. , 2014, Gastroenterology.

[30]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[31]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[32]  M. Kanda,et al.  Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts , 2012, Gut.

[33]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[34]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[35]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[36]  A. Maitra,et al.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways , 2011, Proceedings of the National Academy of Sciences.

[37]  Masakazu Yamamoto,et al.  Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas , 2011, Scientific reports.

[38]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[39]  Y. Tokusashi,et al.  Localization of the Most Severely Dysplastic/Invasive Lesions and Mucin Phenotypes in Intraductal Papillary Mucinous Neoplasm of the Pancreas , 2011, Pancreas.

[40]  T. Furukawa,et al.  Pancreatic Ductal Adenocarcinoma Derived From IPMN and Pancreatic Ductal Adenocarcinoma Concomitant With IPMN , 2011, Pancreas.

[41]  Masakazu Yamamoto,et al.  Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas , 2010, Gut.

[42]  J. Salk.  Clonal evolution in cancer , 2010 .

[43]  N. Sasahira,et al.  Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  R. Hruban,et al.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study , 2005, Virchows Archiv.

[45]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[46]  Michio Shimizu,et al.  An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms , 2004, The American journal of surgical pathology.

[47]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[48]  J. Cameron,et al.  Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray , 2003, Modern Pathology.

[49]  R H Hruban,et al.  Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.